AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04125251 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life Skills Building Training
Description: The Life Skills Building intervention is a curriculum based on 10-12 sessions. The sessions will include the skills essential for family harmony and improving overall mental health of the participants
Study NCT00642642 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Human Fibroblasts (azficel-T)
Description: 1. Collection of 3 mm post auricular skin punch biopsies.~2. Administration of 3 study treatments administered 14 ± 7 days apart.
Study NCT02233478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pomegranate Juice
Description: Pomegranate Juice alone
Study NCT02233478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soybean Flour Protein
Description: Soybean Flour Protein combined with Pomegranate Juice
Study NCT02233478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy Isolate Protein
Description: Soy Isolate Protein combined with Pomegranate Juice
Study NCT01496937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0974
Study NCT01496937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLPG0974
Study NCT02622997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervico-vaginal self-sample taken with first flocked swab
Description: Cervico-vaginal self-sample taken with first flocked swab
Study NCT02622997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervico-vaginal self-sample taken with a second flocked swab
Description: Cervico-vaginal self-sample taken with a second flocked swab
Study NCT02622997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervico-vaginal self-sample taken with a HerSwab device
Description: Cervico-vaginal self-sample taken with a HerSwab device
Study NCT00642642 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. Collection of 3 mm post auricular skin punch biopsies.~2. Administration of 3 study treatments administered 14 ± 7 days apart.
Study NCT03478384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient coaching
Description: Patients receive regular coaching to test if the coaching alters their perceived self-efficacy.
Study NCT00404092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caspofungin
Description: i.v.
Study NCT04278274 — intervention group
Intervention type: PROCEDURE
Intervention: artificial intelligence prediction system
Description: The tumor ROI in the post- neoadjuvant treatment MRI images will be manually delineated, and further subjected to the AI prediction system arm to verify the predictive accuracy of this AI prediction system in identifying the pCR individuals from non-pCR patients with LARC.
Study NCT04548141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Scoring of the IPAQ is performed according to references. Scoring of the SAPHIR has been submitted for copyright protection (involves a series of 23 additions)
Study NCT01557712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine venlafaxine
Description: After a washout period of 7 days of psychotropic medications with the exception of cyamemazine and hydroxyzine:~* Intravenous injection on day 0 to 0.5 mg / kg of ketamine~* D0 to D4: 75 mg of venlafaxine~* D4 to D14: 150 mg per day of venlafaxine~* D14 to D42: 150 mg daily of venlafaxine to 375 mg per day of venlafaxine if patient not responder
Study NCT01557712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: After a washout period of 7 days of psychotropic medications with the exception of cyamemazine and hydroxyzine:~* Intravenous injection on day 0 to 0.5 mg / kg of placebo (saline serum)~* D0 to D4: 75 mg of venlafaxine~* D4 to D14: 150 mg per day of venlafaxine~* D14 to D42: 150 mg daily of venlafaxine to 375 mg per day of venlafaxine if patient not responder
Study NCT04278274 — intervention group
Intervention type: PROCEDURE
Intervention: the radiologists
Description: The enrolled patients will be assigned to the trained experienced radiologists to evaluate their predictive accuracy in identifying the pCR individuals from non-pCR patients
Study NCT01447212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone, Injectable
Description: Phase I: 3x daily, up to 500mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable hydromorphone; 2) switch to oral hydromorphone, for another 6 months.
Study NCT00850174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: 600 mg Tablet
Study NCT00850174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trileptal®
Description: 600 mg Tablet
Study NCT01020396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Vaginal Gel, 0.75%
Study NCT01020396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Vaginal Gel, 0.75%
Study NCT04037969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nesofilcon A
Description: Hydrogel contact lens for daily wear
Study NCT04037969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A
Description: Silicone hydrogel contact lens for daily wear
Study NCT01447212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diacetylmorphine, injectable
Description: Phase I: 3x daily, up to 1,000mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable diacetylmorphine; 2) switch to oral diacetylmorphine, for another 6 months.
Study NCT01447212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone, liquid oral
Description: Study Phase II: After 6 months of receiving Hydromorphone injectable , participants will be randomized to stay on injectable hydromorphone or switch to oral hydromorphone, for another six months. Oral = experimental; injectable = active comparator
Study NCT01447212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diacetylmorphine, liquid oral
Description: Study Phase II: After 6 months of receiving Diacetylmorphine injectable, participants will be randomized to stay on injectable Diacetylmorphine or switch to oral Diacetylmorphine, for another six months. Oral = experimental; injectable = active comparator
Study NCT02232880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
Study NCT02232880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
Study NCT03811275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality (A) then Task (B)
Description: Participants will use their intact arm to perform virtual reality tasks while perceiving a reflected virtual image of their paretic arm.
Study NCT03811275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task (B) then Virtual Reality (A)
Description: Participants will use their paretic arm to perform real tasks in a structured environment, with a practice and feedback schedule organized by a physical or occupational therapist, or graduate student.
Study NCT02848443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil hydrochloride (S 95005)
Description: Film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride, given orally at the dose of 25 or 30 or 35 mg/m2/dose, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
Study NCT02848443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Concentrate for solution for infusion containing 5mg/ml of oxaliplatin, administered intravenously at the dose of 65 to 85 mg/m2, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
Study NCT02848443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Concentrate for solution for infusion containing 25mg/ml of bevacizumab, administered intravenously at the dose of 5 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
Study NCT02848443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Concentrate for solution for infusion containing 10mg/ml of nivolumab, administered intravenously at the dose of 3 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
Study NCT03874260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate vs statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate placebo / once a day, P.O
Study NCT03874260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fenofibrate
Description: statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate vs statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate placebo / once a day, P.O
Study NCT00266864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Transdermal System (Androderm 5 mg patch)
Description: Testosterone Transdermal System (Androderm 5 mg patch)
Study NCT03492008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional technique
Description: Nasogastric tube insertion with patient's head in neutral position
Study NCT03492008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contralateral cricothyroid pressure
Description: Cricothyroid pressure is applied externally in the contralateral direction of selected nostril before nasogastric insertion.
Study NCT03492008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ipsilateral head turning
Description: Patient's head is turned to the ipsilateral side of the selected nostril before nasogastric tube insertion.
Study NCT04045418 — intervention group
Intervention type: DEVICE
Intervention: Laser doppler
Description: A laser doppler flowmetry will be used to measure the microcirculatory characteristics of meridian phenomena. The probes will be left at relevant measuring sites. Blood flow curve and Perfusion units (PU ) will be recorded constantly.~1. Healthy control group and COPD group The probes will be left at Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian for 5 minutes.~2. Healthy intervention group Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.
Study NCT01574833 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed electromagnetic field
Description: PEMF treatment
Study NCT01574833 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham
Description: sham treatment
Study NCT03505710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.
Study NCT02747979 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hemodialysis only
Description: hemodialysis treatment only
Study NCT02747979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hemodialysis only
Description: hemodialysis treatment only
Study NCT02747979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hemodialysis plus hemoperfusion(HA330)
Description: combination of hemodialysis and hemoperfusion (HA330) treatment
Study NCT02747979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hemodialysis plus hemoperfusion(HA130)
Description: combination of hemodialysis and hemoperfusion (HA130) treatment
Study NCT03991546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy Delivered via an Automated Mobile Messaging Robot
Description: Mobile messages utilizing the principles of Acceptance and Commitment therapy. These messages were developed in collaboration with a pain psychologist who specializes in treating chronic pain with Acceptance and Commitment therapy. Subjects received twice-daily messages for two weeks following their orthopaedic procedure.
Study NCT02491359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV
Study NCT02491359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02491359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02491359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03344523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron protein succinylate oral solution
Description: Iron protein succinylate oral solution
Study NCT03344523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: standard treatment
Study NCT03344523 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard treatment
Description: standard treatment
Study NCT01406405 — intervention group
Intervention type: PROCEDURE
Intervention: Posterior/Transforaminal Lumbar Interbody Fusion (P/TLIF), Anterior Cervical Discectomy and Fusion (ACDF)
Description: Lumbar or cervical fusion
Study NCT02122601 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LBSA0103 (BDDE cross-linked sodium hyaluronate gel)
Study NCT01888432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus + reduced tacrolimus
Description: Everolimus was initiated at Week 4 post transplantation. The dose was adjusted to maintain the everolimus trough blood levels between 3-8 ng/mL for the duration of the study. Tacrolimus was reduced to 3-5 ng/mL.
Study NCT01888432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard tacrolimus
Description: Tacrolimus was initiated as soon as possible after transplantation according to approved labeling recommendations. The trough level should've been 5-15 ng/mL until randomization, 8-12 ng/mL from randomization until month 4 and after month 4 until end of study reduced to 6 -10 ng/mL.
Study NCT01073501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study
Study NCT01073501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study
Study NCT04278105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tCES
Description: The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 4 weeks.
Study NCT04278105 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham HD-tCES
Description: The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
Study NCT04278105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper extremity rehabilitation
Description: Upper extremity rehabilitation programs will be selected and graded in accordance with each patient's upper extremity function and specific aims of activities of daily living. Upper extremity rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.
Study NCT01363765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xpert MTB/Rif
Description: Automatized RT-PCR for the detection of Mycobacterium tuberculosis, the agent of TB, in sputum samples
Study NCT01363765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smear microscopy
Description: Sputum smears arriving in the laboratory during the observation period will be submitted to the classic routine smear staining. This would be the non-intervention (control) arm.
Study NCT01552499 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Study NCT01552499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Study NCT04278105 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Upper extremity rehabilitation
Description: Upper extremity rehabilitation programs will be selected and graded in accordance with each patient's upper extremity function and specific aims of activities of daily living. Upper extremity rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.
Study NCT01930331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemisinin/naphthoquine
Description: Each tablet of ARCO (artemisinin/naphthoquine) contains 125 mg artemisinin and 50 mg of naphthoquine. The total dose for adults will be 1000mg of artemisinin and 400mg of naphthoquine in a fixed oral dose (ARCO tablet).~The regimen for children will be calculated according to the body weight (20mg artemisinin + 8mg naphthoquine per kg body weight in a fixed oral dose(ARCO tablet)).
Study NCT01930331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dihydroartemisinin/piperaquine phosphate
Description: Eurartesim (dihydroartemisinin/piperaquine phosphate) is a fixed dose preparation with two dose-strengths (20 mg dihydroartemisinin and 160mg of piperaquine phosphate and 40mg dihydroartemisinin and 320mg of piperaquine phosphate. The regimen for patients with body weight of 36-75kg is three tablets of 40mg dihydroartemisinin and 320mg of piperaquine phosphate once daily for three consecutive days. Those beyond or below this range the regimen will be calculated based on the body weight.
Study NCT04608461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pumpkin seed extract containing cream
Description: Pumpkin seeds extract, white wax, white petrolium, stearyl alcohol
Study NCT03453372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRgFUS Treatment
Description: Treatment of pain caused by knee osteoarthritis with high-intensity focused ultrasound
Study NCT02375867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Description: Oral administration of 1 mg/Kg/day
Study NCT02375867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: Intravenous injection of 0.8 mg/kg/day
Study NCT03543813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-2029
Description: CX-2029 Monotherapy
Study NCT02625584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading Together - Dialogic Reading
Study NCT01649336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162, MEK inhibitor; oral
Description: multiple dose, escalating
Study NCT01649336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, mitotic inhibitor; intravenous
Description: multiple dose, single schedule
Study NCT01219556 — intervention group
Intervention type: DRUG
Intervention: Olmesartan plus hydrochlorothiazide (Xirtam H, BAY98-7105)
Description: Oral Xirtam H tablets every 24 hours (Q24H) or as per prescribing information
Study NCT00738816 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Systematic medication review and advisory notes
Description: Within 24 hours of admission a pharmacist retrieve medication histories from patients included in the intervention group. Medication histories will be obtained from - medical records, medication charts, patients electronical medication profile, interview with patients and if necessary contact to the patients general practitioner. The obtained medication history will be discussed with a physician specialized in pharmacology and an advisory note with suggested changes to the patients medication is added to the medical record. The orthopedic physicians are not obliged to follow the suggested changes
Study NCT03440944 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Peripheral IV Catheter
Description: Patients randomized to this arm will receive an ultrasound guided peripheral IV catheter.
Study NCT03453372 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Procedures in the placebo group will be identical to procedures in the active group, except no sonications (ultrasound emission) will be used.